LambdaGen Therapeutics
Platform biotech using λ‑integrase for precise, large‑payload genome insertion to create next‑gen cell‑therapy and protein‑production solutions.
Private Company
Funding information not available
AI Company Overview
Platform biotech using λ‑integrase for precise, large‑payload genome insertion to create next‑gen cell‑therapy and protein‑production solutions.
Technology Platform
LIGIT is a λ‑integrase mediated site‑specific recombination system that enables precise insertion of large DNA cassettes into safe‑harbor or engineered landing‑pad loci in human cells, allowing seamless genome engineering without viral vectors.
Opportunities
Risk Factors
Competitive Landscape
LambdaGen competes with viral‑vector and CRISPR‑based platforms (e.g., Cellectis, Sangamo) but differentiates through its λ‑integrase system that enables larger, safer insertions and a versatile service offering.